Abstract Number: 196 • 2012 ACR/ARHP Annual Meeting
Sarcoidosis in Northern New England. Clinical Characteristics and Predictive Factors for More Aggressive Therapy
· Background/Purpose: Sarcoidosis is characterized by a variable clinical presentation. DMARDs and biologics have been used for resistant and/or organ-threatening disease. We analyzed the cases…Abstract Number: 197 • 2012 ACR/ARHP Annual Meeting
Collapsing Glomerulopathy in Collagen Vascular-Like Disease
Background/Purpose: Background: Collapsing Glomerulopathy (CG) is an uncommon podocytopathy with distinct clinical and pathological characteristics. It is usually associated with HIV disease or parvovirus B19…Abstract Number: 198 • 2012 ACR/ARHP Annual Meeting
Diagnostic Predictors and Clinical Outcomes in Patients Presenting Solely with Lymphadenopathy
Background/Purpose: Patients presenting solely with radiologic evidence of lymphadenopathy (LAD) to tertiary cancer centers are often diagnosed with malignancy or autoimmune diseases such as sarcoidosis.…Abstract Number: 199 • 2012 ACR/ARHP Annual Meeting
Joint, Hand and Feet Swelling As a Presenting Symptom of Hereditary Angioedema
Background/Purpose: Hereditary Angioedema (HAE) is a rare disorder caused by deficiency or impaired function of C1 esterase inhibitor. Early and accurate diagnosis of HAE is…Abstract Number: 200 • 2012 ACR/ARHP Annual Meeting
Rheumatic Manifestations and Connective Tissue Diseases in Autoimmune Hepatitis of the Child and the Adult
Background/Purpose: Autoimmune hepatitis (AIH) is a progressive fibrosing inflammatory disease of the liver of unknown etiology, leading to cirrhosis. Its course is usually fluctuating and…Abstract Number: 201 • 2012 ACR/ARHP Annual Meeting
High Rate of Autoimmune Manifestations During Idiopathic CD4 Lymphocytopenia
Background/Purpose: When first described by the Center for Disease Control, idiopathic CD4 lymphocytopenia (ICL) was characterized by opportunistic infections in patients with a CD4 count≤300/mm3…Abstract Number: 202 • 2012 ACR/ARHP Annual Meeting
Diseases Associated with Markedly Elevated Ferritin Levels
Background/Purpose: Adult onset Still’s disease (AOSD) is a rare form of inflammatory arthritis with inflammatory systemic disease of unknown etiology. It is a diagnosis of…Abstract Number: 203 • 2012 ACR/ARHP Annual Meeting
Clinical Course Factors Associated with Outcome of Monoarthritis : A Retrospective Study of 173 Cases
Background/Purpose: To evaluate the clinical features and outcomes in patients with monoarthritis and to investigate predictive factors associated with the clinical course in terms of…Abstract Number: 204 • 2012 ACR/ARHP Annual Meeting
Characterization of Joint Disease in Mucopolysaccharidosis Type I Mice and the Effects of Enzyme Replacement Therapy
Background/Purpose: Mucopolysaccharidosis type I (MPS I) is a lysosomal disorder caused by deficiency of alpha-L-iduronidase, which leads to storage of glycosaminoglycans. Patients with MPS I…Abstract Number: 205 • 2012 ACR/ARHP Annual Meeting
Idiopathic Inflammatory Myositis Is Associated with an Increased Incidence of Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) and idiopathic inflammatory myositis (IIM) are two systemic autoimmune connective tissue diseases with predominant effects on skin and muscle respectively .…Abstract Number: 206 • 2012 ACR/ARHP Annual Meeting
Clinical, Laboratory, and Cellular Responses in the Rituximab in Myositis Trial in Patients Enrolled At the National Institutes of Health
Background/Purpose: To assess changes in myositis core set measures, clinical and laboratory data, and paired muscle biopsies from NIH patients enrolled in the Rituximab in…Abstract Number: 167 • 2012 ACR/ARHP Annual Meeting
Serum Uric Acid Control and Risk of Flare According to Different Cut-Offs in Patients with Gout: Longitudinal Analysis From the King Study of the Italian Society for Rheumatology
Background/Purpose: the therapeutic goal of the management of gout is to promote crystal dissolution and prevent crystal formation. For this reason national and international guidelines…Abstract Number: 168 • 2012 ACR/ARHP Annual Meeting
Allopurinol Use Is Associated with a Decreased Risk of Myocardial Infarction
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and the oxidative stress in the vasculature, which are known cardiovascular risk factors. However, the effects…Abstract Number: 169 • 2012 ACR/ARHP Annual Meeting
Post-Marketing Safety Surveillance Data Reveals Patterns of Use for Pegloticase in Refractory Chronic Gout
Background/Purpose: Pegloticase is a recombinant modified mammalian uricase conjugated to mPEG which was approved in the US in 2010 for treating hyperuricemia in patients with…Abstract Number: 170 • 2012 ACR/ARHP Annual Meeting
Relative Risk of Infusion Reactions with KRYSTEXXA® (pegloticase) From Post-Approval Safety Data: Results From Sept 2010 to June 2012
Background/Purpose: During randomized clinical trials (RCTs) with pegloticase, the incidence of infusion-related reactions (IRs) was 26% including 5 cases of anaphylaxis (determined post-hoc using published…